Extended Use of Intravenous Bisphosphonate Therapy for the Prevention of Skeletal Complications in Patients with Cancer

被引：10

作者：

Crawford, Brooke S. ^{[1
]}

McNulty, Robert M. ^{[1
]}

Kraut, Eric H. ^{[2
]}

Turowski, Robert C. ^{[1
]}

机构：

[1] Ohio State Univ, Med Ctr, Dept Pharm, Columbus, OH 43235 USA

[2] Ohio State Univ, Med Ctr, Dept Hematol & Oncol, Columbus, OH 43235 USA

来源：

CANCER INVESTIGATION | 2009年 / 27卷 / 10期

关键词：

Supportive care and symptom control; Late effects of therapy; Breast cancers; Myeloma; Lung cancer; Bisphosphonate; Zoledronic acid; Pamidronate; Osteonecrosis of the jaws; MULTIPLE-MYELOMA; AMERICAN-SOCIETY; ZOLEDRONIC ACID; DOUBLE-BLIND; OSTEONECROSIS; JAW; GUIDELINES; EFFICACY; SAFETY;

D O I：

10.3109/07357900902783203

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Purpose: To evaluate the incidence of skeletal complications in patients with multiple myeloma, and metastatic breast, prostate, or lung cancers, when therapy with intravenous bisphosphonates is continued for longer than 21 months. Methods: The primary outcome was the diagnosis of at least one skeletal-related event (SRE) after 21 months of therapy. The secondary outcome was the incidence of osteonecrosis of the jaws (ONJ). Results: The primary outcome was 30%. The secondary outcome was 3%, while six patients (5%) were referred to a dentist for suspected ONJ. Conclusion: There appears to be a continued benefit when intravenous bisphosphonates are given for longer than 21 months.

引用

页码：984 / 988

页数：5

共 21 条

[1]

Safety and efficacy of bisphosphonates beyond 24 months in cancer patients [J].

Ali, SM ;

Esteva, FJ ;

Hortobagyi, G ;

Harvey, H ;

Seaman, J ;

Knight, R ;

Costa, L ;

Lipton, A .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3434-3437

[2]

Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors [J].

Badros, A ;

Weikel, D ;

Salama, A ;

Goloubeva, O ;

Schneider, A ;

Rapoport, A ;

Fenton, R ;

Gahres, N ;

Sausville, E ;

Ord, R ;

Meiller, T .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :945-952

[3]

American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma [J].

Berenson, JR ;

Hillner, BE ;

Kyle, RA ;

Anderson, K ;

Lipton, A ;

Yee, GC ;

Biermann, JS .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3719-3736

[4]

Bisphosphonates: Clinical experience [J].

Coleman, RE .

ONCOLOGIST, 2004, 9 :14-27

[5]

Durie BGM, 2005, NEW ENGL J MED, V353, P99

[6]

American society of clinical oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer [J].

Hillner, BE ;

Ingle, JN ;

Chlebowski, RT ;

Gralow, J ;

Yee, GC ;

Janjan, NA ;

Cauley, JA ;

Blumenstein, BA ;

Albain, KS ;

Lipton, A ;

Brown, S .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :4042-4057

[7]

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma [J].

Kyle, Robert A. ;

Yee, Gary C. ;

Somerfield, Mark R. ;

Flynn, Patrick J. ;

Halabi, Susan ;

Jagannath, Sundar ;

Orlowski, Robert Z. ;

Roodman, David G. ;

Twilde, Patricia ;

Anderson, Kenneth .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (17) :2464-2472

[8]

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic [J].

Marx, RE .

JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2003, 61 (09) :1115-1117

[9]

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia [J].

Mavrokokki, Tony ;

Cheng, Andrew ;

Stein, Brien ;

Goss, Alastair .

JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2007, 65 (03) :415-423

[10]

MEHROTRA B, 2003, P AN M AM SOC CLIN, V22

← 1 2 3 →